(Q45423583)

English

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis B vaccine

1 reference

based on heuristic

inferred from title

Joanne M. Langley

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Shelly A McNeil

object named as

Shelly McNeil

3

0 references

Scott A Halperin

1

object named as

Scott A Halperin

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Simon Dobson

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Bruce Smith

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Robyn McCall-Sani

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Dan Levitt

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Gary Van Nest

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Daniel Gennevois

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Joseph J Eiden

10

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

12 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

20-26

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Nationwide vaccination: a success story in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

A hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Hepatitis-B Vaccination in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Summary of worldwide clinical experience with H-B-Vax (B, MSD).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Immune activation by bacterial DNA: a new genetic code

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

CpG-rich islands and the function of DNA methylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Activation of human B cells by phosphorothioate oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.095

7 January 2021

Identifiers

10.1016/J.VACCINE.2005.08.095

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45423583&oldid=2076929724"